| abstract |
The present invention relates to an ICOS binding protein or antigen binding portion thereof, and a method for treating cancer, an infectious disease and/or a septicemia using the ICOS binding protein or antigen binding portion thereof, the ICOS binding protein or antigen binding portion thereof It is an agonist of human ICOS, but does not induce complement, ADCC or CDC when it is in contact with T cells in vivo. The ICOS binding protein or antigen-binding portion thereof of the present invention further activates T cells upon contact with T cells; stimulates T cell proliferation upon contact with the T cells and/or induces cytokine production upon contact with the T cells. The invention relates to an ICOS binding protein or antigen binding portion thereof comprising one or more of the following: SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; NO: 5; and/or SEQ ID NO: 6. |